Published

Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysis.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Translational psychiatry
Date: 2025-08-29
Source: PubMed
DOI: 10.1038/s41398-025-03556-4
PubMed: 40883271

Authors

Avanceña ALV Vuong L Kahn JG Marseille E

Watch author

Derived topics and classifications

psilocybin Depression Treatment-Resistant Depression Safety Other

Citation graph

0 referenced DOIs found in stored source metadata. 3 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Reporting practices in psilocybin-assisted therapy trials for depression: A descriptive review and temporal overview2026-07-13 Bringing Psilocybin-Assisted Therapy to Palliative Oncology: Early Lessons from Real-World Implementation2026-06-03 Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysis.2025-08-29

Related papers

A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older AdultsClinicalTrials.gov · 2026-08-10 A Double Blind, Randomized Trial Investigating the Safety, Feasibility, and Mechanisms of Psychedelics in Healthy Older Adults With Low Well-being as Moderated by Biomarkers for Preclinical Alzheimer's DiseaseClinicalTrials.gov · 2026-06-08 Psilocybin may help cancer patients with depression and anxiety for yearsAccess Science · 2020-01-01